Acumen Pharmaceuticals, Inc. Share Price
Equities
ABOS
US00509G2093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.75 USD | -6.46% | -19.12% | -28.39% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17Cr 1.37TCr |
---|---|---|---|---|---|
Net income 2024 * | -6.9Cr -573.26Cr | Net income 2025 * | -9.1Cr -756.04Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | 16Cr 1.36TCr | Net cash position 2025 * | 27Cr 2.24TCr | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.29
x | P/E ratio 2025 * |
-1.89
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.76% |
Latest transcript on Acumen Pharmaceuticals, Inc.
1 day | -6.46% | ||
1 week | -19.12% | ||
Current month | -6.46% | ||
1 month | -21.20% | ||
3 months | -40.73% | ||
6 months | +3.77% | ||
Current year | -28.39% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 01/06/01 |
Jim Doherty
PSD | President | 56 | 01/02 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 01/06/01 |
Director/Board Member | 56 | 01/22/01 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 01/14/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 2.75 | -6.46% | 335,602 |
31/24/31 | 2.94 | -1.34% | 371,129 |
30/24/30 | 2.98 | -2.30% | 396,339 |
29/24/29 | 3.05 | -6.15% | 319,337 |
Delayed Quote Nasdaq, June 04, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.39% | 18Cr | |
+48.64% | 5.46TCr | |
-6.44% | 3.99TCr | |
+37.07% | 3.88TCr | |
+14.28% | 2.69TCr | |
-11.17% | 2.62TCr | |
-21.40% | 1.88TCr | |
+25.64% | 1.22TCr | |
+0.96% | 1.22TCr | |
+27.04% | 1.19TCr |
- Stock Market
- Equities
- ABOS Stock